Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).
C1 esterase inhibitor showed no clear difference in adverse events (during compared with placebo or active control (moderate certainty).
Plasma‐derived C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
The review found no eligible studies for this question.
Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).